15
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Revisiting susceptibility testing in MDR-TB by a standardized quantitative phenotypic assessment in a European multicentre study.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Treatment outcome of MDR-TB is critically dependent on the proper use of second-line drugs as per the result of in vitro drug susceptibility testing (DST). We aimed to establish a standardized DST procedure based on quantitative determination of drug resistance and compared the results with those of genotypes associated with drug resistance.

          Related collections

          Author and article information

          Journal
          J. Antimicrob. Chemother.
          The Journal of antimicrobial chemotherapy
          1460-2091
          0305-7453
          Mar 2015
          : 70
          : 3
          Affiliations
          [1 ] AP-HP, Hôpital Lariboisière, Service de Bactériologie, Centre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux; IAME UMR1137, INSERM, Université Paris Diderot, 75010 Paris, France emmanuelle.cambau@lrb.aphp.fr.
          [2 ] Grupo de Micobactérias, Unidade de Microbiologia Médica, Instituto de Higiene e Medicina Tropical, Universidade Nova de Lisboa (IHMT/UNL), Rua da Junqueira 100, 1349-008 Lisboa, Portugal.
          [3 ] AP-HP, Hôpital Lariboisière, Service de Bactériologie, Centre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux; IAME UMR1137, INSERM, Université Paris Diderot, 75010 Paris, France.
          [4 ] Institut für Medizinische Mikrobiologie, Nationales Zentrum für Mykobakterien, Universität Zürich, Zürich, Switzerland.
          [5 ] IRCCS San Raffaele Scientific Institute, Emerging Bacterial Pathogens Unit Supranational Reference Laboratory, via Olgettina 60, 20132 Milan, Italy.
          [6 ] National Reference Centre of Tuberculosis and Mycobacteria, Communicable and Infectious Diseases, Scientific Institute of Public Health (WIV-ISP), Brussels, Belgium.
          [7 ] Department of Microbiology, Public Health Agency of Sweden and Department of Microbiology, Cell and Tumor Biology, Karolinska Institute, Stockholm, Sweden.
          [8 ] National Reference Center for Mycobacteria, Forschungszentrum Borstel, Borstel, Germany.
          [9 ] Servicio de Microbiología, CH Universitario de Santiago, Centro de Referencia de Micobacterias de Galicia, Choupana S/N, 15705 Santiago de Compostela, Spain.
          [10 ] Tuberculosis Reference Laboratory, National Institute for Public Health and the Environment (RIVM), PO Box 1, 3720 BA Bilthoven, The Netherlands Department of Pulmonary Diseases/Department of Clinical Microbiology, Radboud University Medical Centre, PO Box 9101, Nijmegen, The Netherlands.
          Article
          dku438
          10.1093/jac/dku438
          25587993
          7d655960-6a8e-4440-adb5-84c79634c850
          © The Author 2014. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.
          History

          DST,MGIT,TB eXiST,antibiotic susceptibility testing,antituberculous drugs

          Comments

          Comment on this article